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Abstract: The extracellular matrix (ECM) molecule tenascin C (TNC) is known to be highly expressed
under various pathological conditions such as inflammation and cancer. It has been reported that
the expression of TNC is correlated with the malignant potential of cancer. In our laboratory,
it was found that the peptide derived from the alternative splicing domain A2 in TNC, termed
TNIIIA2, has been shown to influence a variety of cellular processes, such as survival, proliferation,
migration, and differentiation. In this study, we investigated the effect of TNC/TNIIIA2 on the
invasion and metastasis of colon cancer cells, Colon26-M3.1, or PMF-Ko14, using an in vitro and
in vivo experimental system. The degree of cell invasion was increased by the addition of TNC and
TNIIIA2 in a dose-dependent manner. The invasion by TNC and TNIIIA2 were suppressed by an
MMP inhibitor or TNIIIA2-blocking antibody. In an in vivo experiment, pulmonary metastasis was
promoted conspicuously by the addition of TNIIIA2. In this study, we found that colon cancer cell
invasion and metastasis was accelerated by TNC/TNIIIA2 via MMP induction. This result suggests
the possibility of a new strategy targeting TNC/TNIIIA2 for colon cancer.
Keywords: extracellular matrix; tenascin C; TNIIIA2; matrix metalloproteinase; colon cancer
1. Introduction
Many internal cells adhere and depend on the extracellular matrix (ECM). The ECM participates
in various processes, including cell proliferation, survival/death, differentiation, migration, and
adhesion [1,2]. This “anchorage dependent” cell functions are controlled mainly by integrin,
a transmembrane adhesion receptor. Integrin is expressed on the cell membrane as a heterodimer of
two subunits, called the α chain and β chain. Until now, 19 types of α chains and eight types of β
chains have been found, and at least 24 types of different integrin heterodimers were identified by
those combinations [3]. When cells are combined with ECM through integrin, the cytoskeleton system
is constructed in the intracellular domain of integrin and activates various signal molecules [4].
Tenascin C (TNC), one of the ECM components, forms a large structure body outside of the cell by
assembling other ECM and participates in cell adhesion, movement, permeation, survival/migration,
Int. J. Mol. Sci. 2017, 18, 181; doi:10.3390/ijms18010181 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2017, 18, 181 2 of 11
and differentiation [5]. Depending on the cellular context, TNC acts as either an adhesive or an
antiadhesive substrate [6–8]. Because TNC has contradicting actions in cell adhesion, it is classified
as adhesion modulatory ECM. TNC is not expressed in normal cells except in immune tissues, such
as bone marrow and thymus gland [9,10], but is expressed specifically in malignancy, inflammation,
and wound healing. It is reported that the high expression of a molecular variant of TNC was
elevated depending on a malignant potential in the stroma of some malignancies, including oral cancer,
sarcoma, breast cancer, and colon cancer [11–14]. TNC is a large protein with a molecular weight of
250–350 kDa, which is composed a hexamer connecting the polypeptide chain at the N-terminus and a
peptide derived from the selective splice domain A2, called TNIIIA2 [15]. TNIIIA2 is a 22-mer peptide
containing an active sequence YTITIRGV (human), and it has various influences on cell function as
well as the promotion and induction of cell adhesion by the strong and continuous activation of β1
integrin through the syndecan-4 receptor [16], but the expression level of TNIIIA2 in vivo has not been
well known.
However, the morbidity and mortality of colon cancer have recently increased in Japan, ranking
as the third and second most common causes of morbidity and the third and first most common causes
of mortality in males and females, respectively. Risk factors for colon cancer include environmental
factors such as overeating, drinking, and processed meat [17] as well as hereditary diseases such
as familial adenomatous polyposis [18,19]. The increased expression of TNC has been reported in
both inflammatory bowel disease patients and colon cancer patients [14,20,21]. In addition, there
is an association between malignant potential and TNC expression for colon cancer [14], and it is
possible that TNC participates in the malignant transformation of tumors. The increased expression of
TNC macromolecule variant that develops in malignant tumor tissue participates in tumor formation,
migration, and malignant transformation [22]; however, the detailed mechanism by which TNC
participates in such a pathological process based on the sequences involved in biochemical activity is
not clear. Therefore, we performed the following analysis to clarify the participation of TNC and the
functionality of the peptide TNIIIA2 isolated by TNC in the invasion and metastasis of colon cancer
cells in this study.
2. Results
2.1. Functional Analysis of Tenascin C (TNC)/TNIIIA2 in the Invasion of Colon Cancer Cells
An invasion assay was performed to clarify whether TNC or TNIIIA2 had an influence on
the sub-basal membrane invasion of Colon26-M3.1 cells. As a result, both TNC and TNIIIA2
increased invasion in a concentration-dependent manner, and their invasion reached plateau (Figure 1).
Additionally, the results showed that TNC induced Colon26-M3.1 cell invasion significantly but only
weakly, while TNIIIA2 potently induced invasion, but required higher concentrations.
Matrix metalloproteinase (MMP) is an enzyme that breaks down ECM. In the invasion of cancer
cells to the sub-basal membrane, MMP produced by cancer cells destroys the basal membrane
enzymatically and the cancer cells move into that gap [23,24]. It is known that both TNC and MMP
are strongly expressed in tumor tissue [25]; in addition, there are reports that TNC aggravates the
MMP production of cancer cells [26,27]. Therefore, we hypothesized that TNC or TNIIIA2 affected the
promotion of MMP and examined the mRNA expression of MMP-2/9 of Colon26-M3.1 via RT-PCR.
The results showed that TNC was hardly induced in MMP-2 gene expression, but significantly, albeit
weakly, in MMP-9 gene expression. In contrast, TNIIIA2 prominently increased the expression of both
MMP-2 and MMP-9 gene (Figure 2). The results suggest that TNC might have an ability, albeit a weak
one, to induce colon cell invasion at lower concentrations, while TNIIIA2 potently induce the invasion
but requires higher concentrations, as compared to that of TNC.
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Figure 1. Tenascin C (TNC) and the peptide derived from the alternative splicing domain A2 in TNC 
(TNIIIA2) dose-dependently promote Colon26-M3.1 invasion. Colon26-M3.1 cells (3.0 × 104 cells/ 
200 μL/well) were seeded into the upper compartment of the invasion chamber in the presence of 
TNC (A) or TNIIIA2 (B) and were allowed to invade for 24 h. Cells that moved into the lower surface 
of the membranes were stained with crystal violet and counted for four high powered fields. Data 
represent the mean of three determinations ± SD. * p < 0.05. 
 
Figure 2. TNC and TNIIIA2 upregulate the mRNA level of matrix metalloproteinase (MMP)-2,9 of 
Colon26-M3.1. Colon26-M3.1 cells (2.5 × 105 cells/500 μL/well) were seeded onto a 24-well plate in the 
presence or absence of TNC (10 μg/mL) or TNIIIA2 (25 μg/mL) in serum-free medium. After 
incubation for 48 h at 37 °C, the mRNA levels of MMP-2 (A) and MMP-9 (B) were quantified by real-
time RT PCR. Data represent the mean of three determinations ± SD. 
Next, we analyzed the action of TNC on invasion in the presence of MMP inhibitor. The invasion 
by TNC and TNIIIA2 was completely blocked by an MMP inhibitor in Colon26-M3.1 (Figure 3A) and 
PMF-Ko14 (Figure 3B), suggesting that MMP-2/9 secretion from these cells was involved in their 
invasion induced by either TNC or TNIIIA2. 
Figure 1. Tenascin C (TNC) and the peptide derived from the alternative splicing domain A2 in TNC
(TNIIIA2) dose-dependently promote Colon26-M3.1 invasion. Colon26-M3.1 cells (3.0 × 104 cells/
200 µL/well) were seeded into the upper compartment of the invasion chamber in the presence of TNC
(A) or TNIIIA2 (B) and were allowed to invade for 24 h. Cells that moved into the lower surface of the
membranes were stained with crystal violet and counted for four high powered fields. Data represent
the mean of three determinations ± SD. * p < 0.05.
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. T C and TN IIA2 upregulate the mRNA level of matrix metalloproteinase ( MP)-2,9
of Colon26-M3.1. Colon26-M3.1 cells (2.5 × 105 cells 500 µL/well) were seeded onto 24-well
lat in the pre or absence of TNC (10 µg/mL) or TNIIIA2 (25 µg/mL) in serum-free edium.
After incubation for 48 h at 37 ◦C, the mRNA levels of MMP-2 (A) and MMP-9 (B) were quantified by
real-time RT PCR. Data represent th mean of thr e determinations ± SD.
Next, we analyzed the action of TNC on invasion in the presence of MMP inhibitor. The invasion
by TNC and TNIIIA2 was completely blocked by an MMP inhibitor in Colon26-M3.1 (Figure 3A) and
PMF-Ko14 (Figure 3B), suggesting that MMP-2/9 secretion from these cells was involved in their
invasion induced by either TNC or TNIIIA2.
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PMF-Ko14 cells (3.0 × 104 cells/100 μL/well) were seeded onto the upper compartment of the invasion 
chamber with TNC (10 μg/mL) or TNIIIA2 (12.5 μg/mL) and an MMP inhibitor (100 μM) and were 
allowed to invade for 24 h. Cells that invaded the lower surface of the membranes were counted. Data 
represent the mean of three determinations ± SD. 
We previously reported that MMP-2/9 promotes the limited proteolysis of TNC itself as well as 
the basal membrane ECM and isolates the functional component with TNIIIA2 activity [16]. The 
invasion-promoting effect of Colon26-M3.1 and PMF-Ko14 by TNC mentioned above might be a 
component of the effects of isolated TNIIIA2-associated fragments, which were promoted by MMP. 
Therefore, we performed invasion experiments by adding an anti-TNIIIA2 antibody. The results 
show that the invasion-promoting action of TNC and TNIIIA2 was inhibited by the anti-TNIIIA2 
antibody (Figure 4).  
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Data r present the mean of thre determi ations ± SD.
e previously reported that P-2/9 promotes the limited proteolysis of TNC itself as well
as the basal embrane ECM and isolates the functional component with TNIIIA2 activity [16].
The invasion-promoting effect of Colon26-M3.1 and PMF-Ko14 by TNC mentioned above might
be a component of the effects of isolated TNIIIA2-associated fragments, which were promoted by
MMP. Therefore, we performed invasion experiments by adding an anti-TNIIIA2 antibody. The results
show that the invasion-promoting action of TNC and TNIIIA2 was inhibited by the anti-TNIIIA2
antibody (Figure 4).
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allowed to invade for 24 h. Cells that invaded the lower surface of the membranes were stained with 
crystal violet and counted for four high-powered fields. Data represent the mean of three 
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These results suggest that at least one part of the invasion-promoting action of TNC is related to 
the TNIIIA2 component in TNC molecules. In other words, MMP production is promoted by TNC, 
and the mechanism that exposes TNIIIA2 by degradation promotes further invasion. Taken together 
with the results of Figures 1–3, it could be assumed that MMP-9 secretion induced by TNC leads 
TNIIIA2 release from TNC, and the resulting TNIIIA2 further induces induction of MMP-2/9 gene, 
resulting in active invasion of Colon26-M3.1 cells and PMF-Ko14 cells. Thus, weak secretion of MMP-
9 induced by TNC may trigger a positive spiral of MMP-2/9 gene expression through release of 
TNIIIA2. 
2.2. The Effect of TNIIIA2 on a Mouse Model of Metastasis 
The results from in vitro experiments suggest that TNC and TNIIIA2 induce cancer cell invasion 
with producing MMP and might be related to the cell growth factor of mesenchymal cells and the 
induction of cytokine production. Next, we analyzed the action of TNC and TNIIIA2 using a 
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(3.0 × 104 cells/100 µL/ ell) were seeded onto the upper compartment of the invasion chamber with
TNC (10 µg/mL) or TNIIIA2 (12.5 µg/mL) and an anti-TNIIIA2 antibody (10 µg/mL) and were allo ed
to invade for 24 h. Cells that invaded the lower surface of the membranes were stained with crystal
violet and counted for four high-powered fields. Data represent the mean of three determinations± SD.
These results suggest that at least one part of the invasion-promoting action of TNC is related to
the TNIIIA2 component in TNC molecules. In other words, MMP production is promoted by TNC,
and the mechanism that exposes TNIIIA2 by degradation promotes further invasion. Taken together
with the results of Figures 1–3, it could be assumed that MMP-9 secretion induced by TNC leads
TNIIIA2 release from TNC, and the resulting TNIIIA2 further induces induction of MMP-2/9 gene,
resulting in active invasion of Colon26-M3.1 cells and PMF-Ko14 cells. Thus, weak secretion of MMP-9
induced by TNC may trigger a positive spiral of MMP-2/9 gene expression through release of TNIIIA2.
2.2. The Effect of TNIIIA2 on a Mouse Model of Metastasis
The results from in vitro experiments suggest that TNC and TNIIIA2 induce cancer cell invasion
with producing MMP and might be related to the cell growth factor of mesenchymal cells and the
induction of cy okine production. Next, we analyzed the action of TNC and TNIIIA2 using a pulmonary
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metastasis model by injecting Colon26-M3.1 cells into the mouse tail vein. The results show that the
number of the pulmonary nodules increased clearly by the addition of TNC and TNIIIA2. The addition
of TNIIIA2 showed a statistically significant increase in nodules compared to controls (Figure 5).
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TNC is a multifunctional ECM with a variety of actions, and it may have a relationship with the 
malignant potential of colon cancer [14], but its functions are not well understood.  
In this study, it was revealed that the production of MMP-2/9 was increased by TNC or TNIIIA2. 
We previously reported that the proteolysis of TNC by MMP induced the release of functional TNC 
fragments, including TNIIIA2, resulting in the activation of β1 integrin [16]. In addition, Notch 
signaling plays important roles in carcinogenesis in colon cancer [28]. Because Notch signaling is 
thought to be related to MMP-9 activation, TNC or TNIIIA2 might activate Notch signals through the 
production of MMP and participate in tumor invasion. The invasion-promoting effect of TNIIIA2 is 
presumed to participate in the process by which the functional component of TNIIIA2 is exposed by 
limited proteolysis via MMP production and the activation of β1 integrin accelerates further invasion. 
In in vivo experiments that evaluated the pulmonary metastasis of colon cancer cells, pulmonary 
metastasis was facilitated by the combination of TNIIIA2. Two types of metastasis are prevalent: one 
is hematogenous metastasis, in which cancer cells detach from the primary tumor and spread through 
the blood to other organs, and the other is lymphogenous metastasis, in which the cancer cells spread 
Figure 5. TNIIIA2 increases the number of lung metastatic nodules. A Colon26-M3.1 cell suspension
(5.0 × 104 cells/100 µL/head) was injected intravenously into six-week-old Balb/c female mice with or
without TNC (5 µg/head) or TNIIIA2 (5 µg/head, n = 5 each). Fourteen days after injection, the lungs
were stained with Bouin’s fixative. (A) The overview of the lungs of mice injected with Colon26- 3.1
alone, (B) those with TNC, and (C) those with TNIIIA2. The nu ber of lung etastatic nodules was
counted ( ).
3. Discussion
TNC is a multifunctional ECM with a variety of actions, and it may have a relationship with the
malignant potential of colon cancer [14], but its functions are not well understood.
In this study, it was revealed that the production of MMP-2/9 was increased by TNC or TNIIIA2.
We previously reported that the proteolysis of TNC by MMP induced the release of functional TNC
fragments, including TNIIIA2, resulting in the activation of β1 integrin [16]. In addition, Notch
signaling plays important roles in carcinogenesis in colon cancer [28]. Because Notch signaling is
thought to be related to MMP-9 activation, TNC or TNIIIA2 might activate Notch signals through the
production of MMP and participate in tumor invasion. The invasion-promoting effect of TNIIIA2 is
presumed to participate in the process by which the functional component of TNIIIA2 is exposed by
limited proteolysis via MMP production and the activation of β1 integrin accelerates further invasion.
In in vivo experiments that evaluated the pulmonary metastasis of colon cancer cells, pulmonary
metastasis was facilitated by the combination of TNIIIA2. Two types of metastasis are prevalent: one is
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hematogenous metastasis, in which cancer cells detach from the primary tumor and spread through
the blood to other organs, and the other is lymphogenous metastasis, in which the cancer cells spread
through the lymph. In this experiment, we injected cancer cells into the tail vein, which imitated
hematogenous metastasis. Hematogenous metastasis is thought to be constructed in several steps.
The steps include detachment from a primary tumor, permeation or invasion into the blood vessels,
migration from intravascular to extravascular regions, and adhesion or engraftment to organs such
as the lungs or the liver. In this study, it was revealed that TNIIIA2 participates in hematogenous
metastasis after cancer cells infiltrate the blood vessels. Oskarsson et al. reported that TNC derived
from cancer cells contributed to pulmonary micrometastasis and played important roles in the initial
stage of tumor growth [29]. It is thought that the difference in the survival/proliferation of TNIIIA2
depends on the cell strain. Further detailed analysis, including the investigation of human cells in
which TNC is highly expressed or TNIIIA2 is involved in metastasis, is required.
Although it is not clear how TNC or TNIIIA2 participate in cancer invasion, fibroblastic cells
have been reported to be involved in the process. The tumor stroma is composed of fibroblastic
cells, inflammatory cells such as macrophages and various factors, including the ECM protein.
The interaction between epithelial cells and stroma cells plays an important role in the carcinogenic
process, including hyperplasia from normal epithelial cells, the formation of adenoma and malignant
transformation [30]. The TGF-β released from fibroblastic cells is reported to affect the malignant
transformation of cancer cells [31] and promote the function of TNC and participation in cancer
invasion [32]. The relationship between fibroblastic cells and TNIIIA2 has not been clarified, and future
investigation is necessary.
Some reports have mentioned the possibility that the anticancer agent targets TNC. Santis et
al. reported that the monoclonal antibody ST2146 for TNC showed good accumulation in tumor
tissue regardless of the expression of TNC by the analysis of tumor-bearing mice [33]. They suggested
that the chimeric antibody of TNC, which showed high accumulation in brain tumors, could be
used as a therapeutic drug [34]. Other clinical trials have been carried out with some TNC-specific
antibodies [35]. In addition, because the serum and immunohistochemical TNC level is high in colon
cancer and bladder cancer patients, it can act as a tumor marker [36–38]. TNIIIA2, which we analyzed
in this study, might be useful as a tumor marker as well as a target of anticancer agents.
This study has some limitations. Most importantly, we are not able to declare that the data
obtained in this study could be applied widely in human malignancies other than colon cancer.
Other cancers should be examined in addition to colon cancer. It would be important to ascertain if the
anti-cancer effect of anti-TNIIIA2 antibody could be successfully observed also in other cancer cells
and another in vivo xenograft model.
4. Materials and Methods
4.1. Cells and Animals
The mouse colon cancer cell line Colon26-M3.1 was acquired from Saiki at the Division
of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, Toyama,
Japan. Colon26-M3.1 is a mouse epithelial-like transformed colon cell line and well known to
induce lung metastasis by vein injection. Roswell Park Memorial Institute RPMI1640 medium
(Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) with 10% FBS (SAFC Biosciences, St. Louis, MO, USA)
with 0.15% NaHCO3, 2 mM L-glutamine, and 100 µg/mL penicillin-streptomycin (Nacalai Tesque,
Kyoto, Japan) was used for Colon26-M3.1 cell culture. The PMF-ko14 cell was obtained from RIKEN
Bio Resource Center (Tsukuba, Japan). This cell originated from a Japanese colon cancer patient and
was established as cell line. Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich Japan
Co., Ltd., Tokyo, Japan) with 10% FBS (SAFC Biosciences, St. Louis, MO, USA) was used for PMF-ko14
cell culture. Cells were incubated in a 5% CO2 incubator at 37 ◦C.
The Balb/c mice were purchased from Sankyo Laboratory Service Co., Inc. (Tokyo, Japan).
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4.2. Reagents and Instruments
TNC was purified from the culture supernatant of the SK-MEL-28 cells according to methods
reported elsewhere [39]. Refined TNC was confirmed to include a high polymer variant of molecular
weight 250–350 kDa. The cell counting kit and Engelbreth–Holm–Swarm (EHS) sarcoma extract
(Matrigel®) were purchased from Dojindo (Kumamoto, Japan) and AGC Asahi Glass (Tokyo, Japan),
respectively. The synthetic TNIIIA2 peptide (RSTDLPGLKAATHYTITIRGVTC) was purchased
from Eurofins genomics (Whitefield, India). The preparation of antihuman TNIIIA2 polyclonal
antibody has been described previously [40]. In brief, the synthetic peptide CATHYTITIRGVT was
conjugated to KLH (keyhole limpet hemocyanin) as a haptenic antigen and it was immunized to a
rabbit. The IgG fraction of rabbit serum was applied to Sepharose beads coupled with the synthetic
peptide immunogen. Eluted IgG was used as the anti-TNIIIA2 antibody. The MMP-2/-9 inhibitor II,
(2R)-((4-biphenylylsulfonyl)-amino)-N-hydroxy-3-phenylpropionamide (BiPS) was obtained from
Calbiochem (San Diego, CA, USA). The QuantiFast SYBR Green PCR Kit was purchased from
QIAGEN (Hilden, Germany). The Nuclepore Track-Etch Membrane was obtained from Sigma-Aldrich
(St. Louis, MO, USA). We used HITACH MTP-800 Lab (Tokyo, Japan) for absorbance measurements
and the Applied Biosystems 7500 Real-Time PCR system (San Francisco, CA, USA) for RT-PCR.
4.3. Invasion Assay
A transwell chamber was used for invasion assays [41]. The upper chamber and lower chamber
were sterilized by UV irradiation. The porous PVP membrane filter (8.0 µm) was sterilized by autoclave.
Two hundred microliters of medium including 5% FBS was added to the lower chamber and the
membrane filter mentioned above was placed on top without creating air bubbles; this assembly was
attached to the upper chamber. For a basement membrane matrix, EHS sarcoma extract (Matrigel®)
including 1 µg/mL FN was adjusted to 600 µg/mL with PBS solution, and 100 µL were applied to
the membrane filter. The Matrigel® was gelated by incubation at 37 ◦C in a 5% CO2 incubator for one
hour. After removing the supernatant of the gel, Colon26-M3.1 cells (3.0 × 104 cells/200 µL/well)
or PMF-ko14 cells (3.0 × 104 cells/100 µL/well) were seeded and incubated at 37 ◦C in a 5% CO2
incubator for 24 h with various concentrations of TNC or TNIIIA2 with or without an MMP inhibitor
or an anti-TNIIIA2 antibody. After removing non-permeating cells from the membrane filter with a
cotton swab, the invaded cells were fixed by dipping them in a PBS (−) solution including 4% formalin
and 10% glycerol with the undersurface as the top at room temperature for one hour. The invaded
cells were counted in 4–5 areas under a 100×microscope after dying the cells with crystal violet stain.
4.4. RT-PCR
Colon26M3.1 cells (2.5 × 105 cells/500 µL/well) were seeded onto a 24-well plate in the
presence or absence of TNC (10 µg/mL) or TNIIIA2 (25 µg/mL) in a serum-free medium. The cell
RNA was extracted using the PCR RNeasy® Mini Kit (QIAGEN, Hilden, Germany) according
to the manufacturer’s instructions. After the RNA concentration was measured by Nano Drop
(ND-1000 spectrophotometer), cDNA was gathered by the reverse transcription reaction using Quanti
Tect® Reverse Transcription (QIAGEN, Hilden, Germany) and amplified in TaKaRa PCR Thermal
Cycler Dicer (Takara Bio, Shiga, Japan) using various primers (Table 1).
Table 1. The primers for MMP-2 and MMP-9.
GAPDH
Forward: 5′-TTCACCACCATGGAGAAGGC-3′
Reverse: 5′-GGCATGGACTGTGGTCATGA-3′
MMP-2
Forward: 5′-AGATCTTCTTCTTCAAGGACCGGTT-3′
Reverse: 5′-GGCTGGTCAGTGGCTTGGGGTA-3′
MMP-9
Forward: 5′-CACCACCACAACTGAACC-3′
Reverse: 5′-GCCTAGACCCAACTTATCC-3′
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The PCR products were electrophoresed using 2% agarose gel TBE including 0.5 µg/mL EtBr and
developed with a trans-illuminator.
4.5. Animal Model of Metastasis
The Colon26-M3.1 cells suspended in medium including 10% FBS with or without TNC
(5 µg/head) or TNIIIA2 (5 µg/head) were injected to the tail vein of the female Balb/c mice
(6 weeks old, n = 5 each). The lungs were removed 14 days after injection and fixed and stained
with Bouin’s solution. Metastatic foci can be distinguished as whitish colonies from yellowish lung
parenchyma. Surface metastatic foci in lung lobes were counted under a dissecting microscope. All of
the animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC)
of Tokyo University of Science (protocol # Y12032, Y13037, Y14039, Y15002, Y16052; date of approval is
28 March 2012).
4.6. Statistical Analysis
All values are shown as the means ± standard deviation. A two-tailed Student’s t test was used
to analyze the difference between the two groups, and the Student–Newman–Keuls post-hoc test
was used for more than three groups. Statistical analyses were performed with the software Statcel
4 (OMS Publishing Co., Saitama, Japan) and SAS 9.4 (SAS Institute, Cary, NC, USA). A statistically
significant difference was represented by a p-value less than 0.05.
5. Conclusions
In this study, we showed that TNC participated in the malignant transformation of colon cancer
cells through one of its functional components, TNIIIA2. Thus, a new therapeutic strategy for colon
cancer could target TNC/TNIIIA2, and further investigation is needed.
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